Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?

by Poh M.E.; Chai C.S.; Liam C.K.; Ho G.F.; Pang Y.K.; Hasbullah H.H.; Tho L.M.; Nor I.M.; Ho K.F.; Thiagarajan M.; Samsudin A.; Omar A.; Ong C.K.; Soon S.Y.; Tan S.N.; How S.H.
Published in Translational Lung Cancer Research (2024)